Revelation Biosciences, Inc. Common Stock (REVB) Stock Price
REVBStock
$1.05−90.59%52W
Market Cap$4.18M
P/E—
PEG Ratio—
Div yield—
Beta-0.06
REVB Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-34.15%
Price vs S&P 500 (4W)1.40%
VGM Score26.29
REVB Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.83 | -$0.87 | -4.82%(-$0.04) | |
| Q1 2026 | -$1.15 | -$2.71 | -135.65%(-$1.56) | |
| Q4 2025 | -$3.66 | -$1.65 | +54.92%(+$2.01) | |
| Q3 2025 | -$5.34 | -$7.08 | -32.58%(-$1.74) | |
| Q2 2025 | -$24.60 | -$28.04 | -13.98%(-$3.44) |
REVB Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
REVBRevelation Biosciences, Inc. Common Stock | — | — | D | $1.05 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Revelation Biosciences, Inc. Common Stock
Revelation Biosciences is a clinical-stage biotech company developing immunology-based treatments using Gemini, a proprietary TLR4 agonist designed to modulate inflammatory responses for therapeutic benefit. The company's pipeline includes three Gemini-based programs: Gemini-SSI for surgical site infection prevention, Gemini-AKI for acute kidney injury prevention, and Gemini-CKD for chronic kidney disease treatment.